SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Journal: Nature

Published: 2020-08-05

DOI: 10.1038/s41586-020-2622-0

Affiliations: 9

Authors: 62

Go to article
Institutions Share
NIH NIAID Vaccine Research Center (VRC), United States of America (USA) 0.40
Moderna Therapeutics, Inc., United States of America (USA) 0.29
UNC Department of Epidemiology, United States of America (USA) 0.10
NIH National Institute of Allergy and Infectious Diseases (NIAID), United States of America (USA) 0.06
Department of Pediatrics, VU, United States of America (USA) 0.05
Department of Molecular Biosciences, UT Austin, United States of America (USA) 0.05
UNC Department of Microbiology and Immunology, United States of America (USA) 0.02
NIH NIAID Division of Clinical Research (DCR), United States of America (USA) 0.02
Institute for Biomedical Sciences (IBS), GW, United States of America (USA) 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER